Curative Effect of Aprepitant Preventing CINV.
10.3779/j.issn.1009-3419.2018.10.12
- Author:
Shasha GUAN
1
;
Lisha ZHANG
1
;
Diansheng ZHONG
1
;
Qing MA
1
;
Fanlu MENG
1
;
Yi SHAO
1
;
Tao YU
1
;
Xia LIU
1
Author Information
1. Department of Medical Oncology, Tianjin Medical University General Hospital, Tianjin 300052, China.
- Publication Type:Journal Article
- Keywords:
Aprepitant;
CINV;
Cancer;
Cisplatin
- MeSH:
Adult;
Aged;
Aged, 80 and over;
Antineoplastic Agents;
adverse effects;
Aprepitant;
Cisplatin;
adverse effects;
Female;
Humans;
Male;
Middle Aged;
Morpholines;
pharmacology;
Nausea;
chemically induced;
prevention & control;
Quality of Life;
Vomiting;
chemically induced;
prevention & control
- From:
Chinese Journal of Lung Cancer
2018;21(10):800-804
- CountryChina
- Language:Chinese
-
Abstract:
BACKGROUND:Chemotherapy is the most important method for cancer treatment. However, chemotherapy induced nausea and vomiting (CINV) has a profound effect on patients. In recent years, there have been new antiemetic drugs, such as aprepitant. We review the curative effect of aprepitant with tropisetron and dexamethasone for prevention of nausea and vomiting in patients receiving Cisplatin chemotherapy.
METHODS:Observation is divided into three stages. Whole study phase (0-120 h after chemotherapy administration), acute phases (0-24 h), and delayed phase (24 h-120 h). The primary endpoints were complete response (CR) and complete prevention (CP) during the three different study phase.
RESULTS:In the whole study phase, 86.02% of patients achieved CR; in acute phases and delayed phases were 89.25%, 87.1%, respectively. CP were 46.22%, 83.87%, 45.16%, respectively. Anti-CINV effect was significantly associated with age distribution (P=0.008).
CONCLUSIONS:Aprepitant with tropisetron and dexamethasone prevented effectively CNIV for patients receiving Cisplatin chemotherapy. This combination could improve the quality of life and the compliance of patient with chemotherapy.
